These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 25818471

  • 1. Onartuzumab in lung cancer: the fall of Icarus?
    Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F.
    Expert Rev Anticancer Ther; 2015 May; 15(5):487-9. PubMed ID: 25818471
    [Abstract] [Full Text] [Related]

  • 2. Onartuzumab ineffective in non-small-cell lung cancer.
    Brower V.
    Lancet Oncol; 2017 Feb; 18(2):e66. PubMed ID: 28017663
    [No Abstract] [Full Text] [Related]

  • 3. Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer.
    Han K, Chanu P, Jonsson F, Winter H, Bruno R, Jin J, Stroh M.
    AAPS J; 2017 Mar; 19(2):527-533. PubMed ID: 28028730
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [THE CURRENT APPROACH TO ADVANCED LUNG CANCER].
    Gottfried M, Keizman D, Mishaeli M, Maimon Rabinovich N.
    Harefuah; 2015 Aug; 154(8):521-4, 539-40. PubMed ID: 26480619
    [Abstract] [Full Text] [Related]

  • 9. Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
    ESMO Guidelines Committee.
    Ann Oncol; 2017 Jul 01; 28(suppl_4):iv158-iv161. PubMed ID: 28881928
    [No Abstract] [Full Text] [Related]

  • 10. First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era.
    Capelletto E, Novello S, Scagliotti GV.
    Future Oncol; 2014 May 01; 10(6):1081-93. PubMed ID: 24941991
    [Abstract] [Full Text] [Related]

  • 11. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
    Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A.
    J Clin Oncol; 2005 Apr 10; 23(11):2544-55. PubMed ID: 15753462
    [Abstract] [Full Text] [Related]

  • 12. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA, TRIBUTE Investigator Group.
    J Clin Oncol; 2005 Sep 01; 23(25):5892-9. PubMed ID: 16043829
    [Abstract] [Full Text] [Related]

  • 13. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J.
    Clin Ther; 2005 Oct 01; 27(10):1513-34. PubMed ID: 16330289
    [Abstract] [Full Text] [Related]

  • 14. Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers.
    Genova C, Rijavec E, Grossi F.
    Expert Rev Anticancer Ther; 2016 Oct 01; 16(1):1-4. PubMed ID: 26567561
    [Abstract] [Full Text] [Related]

  • 15. First-line treatment for advanced non-small-cell lung cancer.
    Laskin JJ, Sandler AB.
    Oncology (Williston Park); 2005 Nov 01; 19(13):1671-6; discussion 1678-80. PubMed ID: 16425521
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG, Maitland ML, Stadler WM, Ratain MJ.
    J Natl Cancer Inst; 2007 Oct 03; 99(19):1455-61. PubMed ID: 17895472
    [Abstract] [Full Text] [Related]

  • 18. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
    Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, Soria JC, von Pawel J, Schwartz B, Von Roemeling R, Sandler AB.
    Clin Lung Cancer; 2012 Sep 03; 13(5):391-5. PubMed ID: 22440336
    [Abstract] [Full Text] [Related]

  • 19. Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: current status and future challenges.
    Pallis AG, Syrigos K.
    Cancer Treat Rev; 2012 Nov 03; 38(7):861-7. PubMed ID: 22217701
    [Abstract] [Full Text] [Related]

  • 20. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
    Sandler A, Herbst R.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 2):4421s-4425s. PubMed ID: 16857821
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.